Skip to main content

Table 3 Univariate and multivariate analyses of overall survival

From: C-reactive protein/albumin ratio and Glasgow prognostic score are associated with prognosis and infiltration of Foxp3+ or CD3+ lymphocytes in colorectal liver metastasis

 

N

Event

Univariate

Multivariatea

95% CI

HR

p-value

95% CI

HR

p-value

95% CI

HR

p-value

Sex

           

 Female

42

19

1

      

 Male

75

35

0.57-1.76

1.00

0.986

      

Age

           

 ≥70

40

17

1

      

 <70

77

37

0.60-1.91

1.07

0.809

      

Primary tumor location

           

 Left

85

39

1

      

 Right

32

15

0.61-2.01

1.11

0.738

      

NAC

           

 Yes

47

26

1

1

1

 No

70

28

0.34-0.99

0.58

0.045*

0.47-1.59

0.86

0.636

0.44-1.46

0.80

0.464

Preoperative CEA

           

 ≥5

83

41

1

      

 <5

34

13

0.34-1.21

0.64

0.169

      

Onset

           

 Synchronous

61

33

1

1

1

 Metachronous

56

21

0.29-0.87

0.50

0.014*

0.33-1.15

0.61

0.126

0.32-1.09

0.59

0.090

Tumor location

           

 Hemilobar

72

28

1

1

1

 Bilobar

45

26

1.09-3.20

1.86

0.024*

0.84-2.69

1.51

0.165

0.85-2.66

1.50

0.163

Tumor diameter

           

 ≥50

23

12

1

      

 <50

94

42

0.33-1.21

0.63

0.165

      

Tumor number

           

 Multiple

63

33

1

      

 Solitary

54

21

0.36-1.10

0.63

0.102

      

NLR

           

 ≥2.03

59

28

1

      

 <2.03

58

26

0.50-1.46

0.86

0.571

      

PLR

           

 ≥134

59

28

1

      

 <134

58

26

0.46-1.34

0.78

0.372

      

CAR

        

 ≥0.030

59

33

1

1

   

 <0.030

58

21

0.31-0.93

0.54

0.027*

0.33-0.99

0.57

0.048*

   

GPS

     

   

 1/2

13

9

1

   

1

 0

104

45

0.20-0.84

0.41

0.015*

   

0.19-0.83

0.40

0.013*

  1. aAdjusted for the following variables: NAC, Onset, Tumor location
  2. CAR C-reactive protein/albumin ratio, CEA carcinoembryonic antigen, CI confidence interval, HR hazard ratio, GPS Glasgow prognostic score, NAC neoadjuvant chemotherapy, NLR neutrophil/lymphocyte ratio, PLR platelet/lymphocyte ratio